Review anchor
RAC-beta serine/threonine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
RAC-beta serine/threonine-protein kinase
CHEMBL2431
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RAC-beta serine/threonine-protein kinase as ChEMBL target CHEMBL2431, mapped to UniProt P31751. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2431
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31751
RAC-beta serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why RAC-beta serine/threonine-protein kinase matters
RAC-beta serine/threonine-protein kinase is reviewed as RAC-beta serine/threonine-protein kinase (UniProt P31751); RAC-beta serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 3417 compounds, and 546 assays, with lead potency reaching pChEMBL 9.7.
Protein context
RAC-beta serine/threonine-protein kinase
RAC-beta serine/threonine-protein kinase Sequence length is 481 aa.
Review this target as RAC-beta serine/threonine-protein kinase, mapped to UniProt P31751. Sequence length is 481 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P31751
Protein
Disease context
neoplasm
RAC-beta serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm. 1 linked drug keep the rationale reviewable. Linked drugs include BAY-1125976.
Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BAY-1125976. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 3417 compounds, and 546 assays for this target. The dominant activity type is IC50. CHEMBL4440965 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL4440965 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 9.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why RAC-beta serine/threonine-protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31751, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3417
Total Compounds
546
Total Assays
4
Approved Drugs
IC50: 1699.0, KI: 815.0, EC50: 19.0, KD: 375.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4440965
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL3701767
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL3701740
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL3701766
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL3701717
|
9.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAPIVASERTIB
CHEMBL2325741
|
2023 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
Source Header